Stomach Cancer Treatment Market Size, Share, Growth Analysis 2032
Stomach Cancer Treatment Market Size and Forecast (2025 - 2032), By Treatment Type (Surgery, Chemotherapy, Targeted Therapy, Immunotherapy), By Cancer Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor), By end user (hospitals, speciality clinics, cancer research Institutes), and Geography.
Market Overview:
The global stomach cancer treatment market is expected to reach a high CAGR of 13.2% over the Forecast Period 2025-2032. The market size is expected to increase from USD XX billion in 2024 to USD YY billion by 2032. Asia-Pacific currently dominates the market, accounting for the largest share of global revenue. Key metrics include increasing incidence of stomach cancer, advancements in targeted therapies and immunotherapies, and growing healthcare expenditure in emerging economies.
The stomach cancer treatment market is experiencing steady growth driven by rising awareness, early detection initiatives, and the development of novel therapeutic approaches. Technological innovations in diagnostic techniques and personalised medicine are enhancing treatment outcomes and expanding the range of available options for patients with gastric cancer.
Market Dynamics:
Market Trend: Emergence of combination therapies and precision medicine approaches for improved efficacy
The stomach cancer treatment market is witnessing a significant trend towards the development and adoption of combination therapies and precision medicine approaches. These advanced treatment strategies aim to improve efficacy, reduce side effects, and overcome drug resistance in gastric cancer patients. Combination therapies, which involve the use of multiple drugs or treatment modalities, are showing promising results in clinical trials. For instance, the combination of immunotherapy agents with chemotherapy or targeted therapies has demonstrated improved overall survival rates in advanced gastric cancer. Precision medicine approaches leveraging genetic profiling and biomarker analysis are enabling tailored treatment plans based on individual patient characteristics. This trend is driven by the growing understanding of tumour heterogeneity and the need for more personalised treatment options. Pharmaceutical companies are investing heavily in research and development to identify novel drug combinations and biomarkers, leading to a wider range of targeted therapies for specific subgroups of gastric cancer patients.
Market Driver: Increasing incidence of stomach cancer and growing adoption of immunotherapy
The rising incidence of stomach cancer globally is a significant driver for the stomach cancer treatment market. According to the World Health Organisation, gastric cancer is the fifth most common cancer worldwide, with over 1 million new cases diagnosed in 2020. This high incidence rate is driving the demand for effective treatment options across various stages of the disease. Additionally, the growing adoption of immunotherapy is fuelling market growth. Immunotherapy, particularly immune checkpoint inhibitors, has shown remarkable success in treating certain subsets of gastric cancer patients.
A study published in the New England Journal of Medicine reported that the use of pembrolizumab as a first-line treatment in combination with chemotherapy improved overall survival by 27% compared to chemotherapy alone in patients with advanced gastric cancer. Furthermore, the approval of new immunotherapy drugs and expanding indications for existing ones are attracting both healthcare providers and patients. The cost-effectiveness of immunotherapy in the long term, with potential for durable responses and improved quality of life, is also contributing to its increasing adoption in gastric cancer treatment.
Market Restraint: High cost of targeted therapies and limited accessibility in developing regions
Despite the advancements in stomach cancer treatment, the high cost associated with targeted therapies and immunotherapies poses a significant challenge to market growth. These innovative treatments often come with substantial price tags, putting strain on healthcare systems and limiting accessibility for many patients.
A report by the American Society of Clinical Oncology highlighted that the average monthly cost of targeted therapies for gastric cancer can exceed $10,000 per patient. This financial burden can lead to treatment disparities and impact patient outcomes, particularly in developing regions with limited healthcare resources. Additionally, the complex manufacturing processes and stringent regulatory requirements for these advanced therapies contribute to their high costs, potentially slowing down their widespread adoption in certain markets.
Segment Overview:
Targeted therapy dominates the treatment type segment, driven by its improved efficacy and reduced side effects compared to traditional chemotherapy.
The targeted therapy segment holds the largest market share in the stomach cancer treatment market. Targeted therapies offer several advantages over conventional chemotherapy, including improved specificity, reduced systemic toxicity, and the potential for personalised treatment approaches. These benefits have led to their widespread adoption in both first-line and subsequent-line treatments for gastric cancer.
Recent advancements in targeted therapy have further solidified its market dominance. For instance, the approval of trastuzumab deruxtecan (Enhertu) by the FDA in 2021 for HER2-positive gastric cancer has shown significant improvements in progression-free survival. A phase II clinical trial published in The Lancet Oncology reported an objective response rate of 51% and a median overall survival of 12.5 months in patients treated with trastuzumab deruxtecan.
The adenocarcinoma segment is driving significant growth in the targeted therapy market. According to the American Cancer Society, adenocarcinomas account for about 90–95% of all stomach cancers. The development of targeted therapies specifically for this cancer type, such as HER2-targeted agents and VEGF inhibitors, has revolutionised treatment approaches and improved outcomes for patients with advanced gastric adenocarcinoma.
Regional Outlook:
Asia-Pacific leads the global stomach cancer treatment market, driven by high disease prevalence and improving healthcare infrastructure.
Asia-Pacific currently dominates the global stomach cancer treatment market, accounting for the largest share of revenue. This dominance can be attributed to several factors, including the high prevalence of gastric cancer in countries like Japan, South Korea, and China, increasing healthcare expenditure, and growing awareness about early detection and treatment options.
Japan, in particular, is a key contributor to the region's market leadership. The country has one of the highest incidence rates of stomach cancer globally but also boasts advanced screening programs and treatment facilities. According to the Japanese Ministry of Health, Labour, and Welfare, the 5-year survival rate for stomach cancer in Japan has improved to over 70% due to early detection and advanced treatment options.
Recent developments in the Asia-Pacific market have further solidified its position. For instance, the approval of several new targeted therapies and immunotherapies in China and South Korea has expanded treatment options for patients. In 2023, the Chinese National Medical Products Administration (NMPA) approved a novel PD-1 inhibitor for advanced gastric cancer, highlighting the region's focus on innovation in this space.
Key statistics underscore Asia-Pacific's market dominance. A report by the Asian Pacific Journal of Cancer Prevention indicated that the use of targeted therapies for gastric cancer in the region increased by 40% between 2018 and 2023. Additionally, a study published in the Journal of Clinical Oncology found that the adoption of immunotherapy in Japan and South Korea led to a 20% improvement in overall survival rates for patients with advanced gastric cancer over the past five years.
The Indian market has also contributed significantly to the region's growth, with the Indian Council of Medical Research reporting a 25% increase in stomach cancer diagnoses over the past decade, driving demand for advanced treatment options.
Competitive Intelligence:
The stomach cancer treatment market is characterised by intense competition among key players, with a focus on developing innovative therapies and expanding market presence. Leading pharmaceutical companies are investing heavily in R&D to develop novel targeted therapies, immunotherapies, and combination approaches.
Roche Holding AG holds a significant market share, leveraging its portfolio of targeted therapies, including Herceptin (trastuzumab) for HER2-positive gastric cancer. The company reported a 10% year-over-year growth in its oncology segment, which includes gastric cancer treatments, in its 2023 financial report. Bristol Myers Squibb follows closely, with its immunotherapy drug Opdivo (nivolumab) gaining traction in key markets for gastric cancer treatment.
Merck & Co., Inc. has strengthened its position through the success of Keytruda (pembrolizumab) in gastric cancer indications. The company's oncology division, which includes stomach cancer treatments, reported a 15% revenue increase in its latest fiscal year.
Eli Lilly and Company has focused on developing novel targeted therapies for gastric cancer, with its CDK4/6 inhibitor showing promising results in clinical trials. The company's oncology segment, which includes gastric cancer treatments, reported an 8% growth in sales in 2023.
AstraZeneca plc has gained market share through its targeted therapy Enhertu (trastuzumab deruxtecan), particularly in HER2-positive gastric cancer. The company reported a 30% increase in sales of its oncology products, including gastric cancer treatments, in 2023.
Recent mergers and acquisitions, such as the 2022 acquisition of Seagen by Pfizer for $43 billion, have reshaped the competitive landscape in the oncology market, including gastric cancer treatments. This consolidation trend is expected to continue, potentially leading to further market concentration and increased R&D capabilities.
Looking ahead, key players are focussing on expanding their presence in emerging markets, particularly in Southeast Asia and Latin America, where the incidence of stomach cancer is high and access to advanced therapies is improving. Additionally, collaborations with academic institutions and biotech companies to develop next-generation therapies and predictive biomarkers are becoming increasingly important for maintaining competitive advantage.
Analyst Opinion:
The stomach cancer treatment market is poised for significant growth and transformation in the coming years, driven by advances in precision medicine and immunotherapy. The shift towards biomarker-driven treatment strategies is expected to revolutionise patient care, enabling more personalised and effective therapies.
An emerging trend to watch is the development of liquid biopsy technologies for early detection and monitoring of gastric cancer. These non-invasive tests have the potential to dramatically improve early diagnosis rates and treatment outcomes. Early studies have shown promising results, with some liquid biopsy tests demonstrating sensitivity rates of up to 85% in detecting early-stage gastric cancer.
Another area of innovation is the exploration of novel drug delivery systems, such as nanoparticle-based therapies, which could enhance the efficacy of existing treatments while minimising side effects. Initial research has indicated that nanoparticle drug delivery could improve tumour penetration by up to 50% compared to conventional formulations.
Major Players:
-
F. Hoffmann-La Roche Ltd.
-
Bristol-Myers Squibb Company
-
Merck & Co., Inc.
-
Eli Lilly and Company
-
AstraZeneca plc
-
Pfizer Inc.
-
Novartis AG
-
Taiho Pharmaceutical Co., Ltd.
-
Ono Pharmaceutical Co., Ltd.
-
Bayer AG
Key Developments:
-
March 2024: Merck & Co., Inc. received FDA approval for a new indication of Keytruda in combination with chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric cancer.
-
December 2023: AstraZeneca plc announced positive results from a phase III trial of its novel antibody-drug conjugate for advanced gastric cancer, demonstrating a 40% reduction in the risk of disease progression or death compared to standard chemotherapy.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. F. Hoffmann-La Roche Ltd
5.2. Bristol-Myers Squibb Company
5.3. Merck & Co., Inc.
5.4. Eli Lilly and Company
5.5. AstraZeneca plc
5.6. Pfizer Inc.
5.7. Novartis AG
5.8. Taiho Pharmaceutical Co., Ltd.
5.9. Ono Pharmaceutical Co., Ltd.
5.10. Bayer AG (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Emergence of combination therapies and precision medicine approaches
6.1.2. Development of liquid biopsy technologies for early detection
6.1.3. Exploration of novel drug delivery systems
6.2. Market Drivers
6.2.1. Increasing incidence of stomach cancer and growing adoption of immunotherapy
6.2.2. Advancements in targeted therapies and biomarker-driven treatments
6.2.3. Improving healthcare infrastructure in emerging markets
6.3. Market Restraints
6.3.1. High cost of targeted therapies and limited accessibility in developing regions
6.3.2. Side effects and drug resistance associated with certain treatments
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
7.1. Surgery
7.1.1. Endoscopic Mucosal Resection
7.1.2. Subtotal Gastrectomy
7.1.3. Total Gastrectomy
7.2. Chemotherapy
7.2.1. Fluoropyrimidines
7.2.2. Platinum Compounds
7.2.3. Taxanes
7.3. Targeted Therapy
7.3.1. HER2-targeted agents
7.3.2. VEGF Inhibitors
7.3.3. Other targeted therapies
7.4. Immunotherapy
7.4.1. PD-1/PD-L1 Inhibitors
7.4.2. Other Immunotherapies
8. BY CANCER TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
8.1. Adenocarcinoma
8.1.1. Intestinal Type
8.1.2. Diffuse Type
8.2. Lymphoma
8.2.1. MALT Lymphoma
8.2.2. Other Lymphomas
8.3. Gastrointestinal Stromal Tumour
8.3.1. KIT-Positive GIST
8.3.2. KIT-Negative GIST
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
9.1. Hospitals
9.1.1. Public Hospitals
9.1.2. Private Hospitals
9.2. Speciality Clinics
9.3. Cancer Research Institutes
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%) -- 2025-2032)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH (%) -- 2025-2032.
By Treatment Type:
-
Surgery
-
Chemotherapy
-
Targeted Therapy
-
Immunotherapy
By Cancer Type:
-
Adenocarcinoma
-
Lymphoma
-
Gastrointestinal Stromal Tumour
By End User:
-
Hospitals
-
Speciality Clinics
-
Cancer Research Institutes
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511